hUCMSCs
Phase 2Biologic
hUCMSCs is one of 46 biologic programs targeting Premature ovarian insufficiency. It is currently in Phase 2.
2
Indications
2
Total Trials
0
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
252 competitors in Cirrhosis
#DrugCompanyPhaseTrials
1Proamatine
TakedaPreclinical
Crestor
AstraZenecaPreclinical
Thalomid
Bristol-Myers SquibbPreclinical
Farxiga
AstraZenecaPreclinical
Azulfidine
PfizerPreclinical
Dobutrex
Eli LillyPreclinical
Coreg
Akero TherapeuticsPreclinical
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Cialis
Eli LillyPreclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for hUCMSCs. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- SSclnow Biotechnology Co., Ltd.